Stock profile

Aarti Drugs Limited(AARTIDRUGS.NS)

Country: IndiaSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: NSE
P/E TTM
20.0
History
P/E NTM
20.6
Market cap
37.6B
Currency INR
KvantraRanki56
Value67
Quality53
Momentum44
Current price
427.70-0.88%
Benchmarks

No price history available.

Key financial summary

Financials in INR
2020202120222023202420252026TTM2027E
Total revenueINRm18,06121,54824,88627,16125,28623,87025,653N/AN/A
Operating profitINRmLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net profitINRm1,4142,8042,0501,6631,7141,6821,949N/AN/A
EPS reportedINRLockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per shareINRLockedLockedLockedLockedLockedLockedLockedLockedLocked
Capex per shareINRLockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF per shareINRLockedLockedLockedLockedLockedLockedLockedLockedLocked
Free cash flowINRmLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debtINRmLockedLockedLockedLockedLockedLockedLockedLockedLocked
Book value equityINRmLockedLockedLockedLockedLockedLockedLockedLockedLocked
Book value per shareINRLockedLockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)INRLockedLockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in INR
2020202120222023202420252026TTM2027E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLockedLocked

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Company overview

Operating both within India and globally, Aarti Drugs Limited, along with its affiliated companies, specializes in the pharmaceutical sector. Its product portfolio encompasses a wide range of active pharmaceutical ingredients (APIs) across numerous therapeutic areas, such as anti-inflammatory, cardiovascular protection, antidiarrheal, antifungal, anti-arthritis/osteoporosis, antibiotic, antidiabetic, Alzheimer's disease management, sedative, vitamin, and alcoholism treatment. Additionally, it supplies pharmaceutical intermediate compounds, including tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. Furthermore, the company manufactures and distributes various specialty chemicals. These include a comprehensive list of compounds such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, sodium benzene sulfinate, para toluene sulphonyl hydrazide, benzene sulphonic acid and its sodium salt, benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. Aarti Drugs also maintains a robust development pipeline, featuring products such as Acamprosate, intended for treating alcoholism; Dabigatran, an anticoagulant; Sevelamer, for managing hyperphosphatemia; Colesevelam, aimed at lowering cholesterol; Dronedarone and Olmesartan, both for cardiovascular disease treatment; Valsartan, which acts as a cardioprotectant; and Sitagliptin, an antidiabetic agent. Moreover, the firm provides contract manufacturing solutions. Established in 1984, the company's main operations are based in Mumbai, India.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryIndia
Trades inINR

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Aarti Drugs Limited (AARTIDRUGS.NS)

AARTIDRUGS.NS · NSE · Healthcare
427.70-0.88%
Sign up to track this stock

No price history available.

KvantraRank56
P/E TTM20.0
P/E NTM20.6
Market cap37.6B
KvantraRank?56 / 100
Value
67
Quality
53
Momentum
44
Financialsin INR
20242025TTM2026
Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

About

Operating both within India and globally, Aarti Drugs Limited, along with its affiliated companies, specializes in the pharmaceutical sector. Its product portfolio encompasses a wide range of active pharmaceutical ingredients (APIs) across numerous therapeutic areas, such as anti-inflammatory, cardiovascular protection, antidiarrheal, antifungal, anti-arthritis/osteoporosis, antibiotic, antidiabetic, Alzheimer's disease management, sedative, vitamin, and alcoholism treatment. Additionally, it supplies pharmaceutical intermediate compounds, including tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. Furthermore, the company manufactures and distributes various specialty chemicals. These include a comprehensive list of compounds such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, sodium benzene sulfinate, para toluene sulphonyl hydrazide, benzene sulphonic acid and its sodium salt, benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. Aarti Drugs also maintains a robust development pipeline, featuring products such as Acamprosate, intended for treating alcoholism; Dabigatran, an anticoagulant; Sevelamer, for managing hyperphosphatemia; Colesevelam, aimed at lowering cholesterol; Dronedarone and Olmesartan, both for cardiovascular disease treatment; Valsartan, which acts as a cardioprotectant; and Sitagliptin, an antidiabetic agent. Moreover, the firm provides contract manufacturing solutions. Established in 1984, the company's main operations are based in Mumbai, India.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryIndia
Trades inINR

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans